A Multicenter, Randomized, Open-label Study to Investigate the combination therapy of AL-335, Odalasvir, and Simeprevir in Treatment-naive and Treatment-experienced Subjects With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5, and 6 Infection Without Cirrhosis
Latest Information Update: 24 Sep 2016
At a glance
- Drugs AL 335/odalasvir/simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 24 Sep 2016 New trial record